Guidelines December 15, 2022
Heart Disease Care in an Aging Population December 15, 2022
With the US facing an aging population, the AHA’s latest scientific statement provides timely information on the diagnosis and management of ACS in adults over 75.
Cardiovascular Disease December 12, 2022
Childhood Lp(a) Predicts Adult CVD Risk December 12, 2022
Individuals who had high Lp(a) levels when they were young were twice as likely to develop atherosclerotic cardiovascular disease in middle age.
Surgeries & Interventions December 8, 2022
Interventional Cardiology Joins The Match for 2025 December 8, 2022
Prospective IC fellows can breathe a sigh of relief. Starting in 2025, three-quarters of interventional cardiology fellowship programs will transition to a voluntary match system.
Guidelines December 5, 2022
Is 8 Minutes of Exercise Enough? December 5, 2022
A mere eight minutes of exercise a day – 54 minutes a week – is enough to lower risk of early death and heart disease.
Cardiovascular Disease December 1, 2022
ADHD Meds & Cardiovascular Disease December 1, 2022
New findings suggest ADHD medications — which have raised concerns about CVD risk — are safe for the heart.
Cardiology Pharmaceuticals November 28, 2022
FDA Warns 7 Supplement Companies for Illegally Claiming CV Benefits November 28, 2022
Just weeks after results from the SPORT trial showed no cholesterol benefit from common heart supplements, the FDA has issued warning letters to seven companies for illegally selling dietary supplements that claim to cure, treat, mitigate, or prevent cardiovascular disease.
Cardiology Pharmaceuticals November 21, 2022
Aprocitentan: The New Antihypertensive on the Block November 21, 2022
Aprocitentan has proved itself a promising new agent for blood pressure control. In the PRECISION trial, aprocitentan lowered both office and 24-hour ambulatory BP among people with resistant hypertension.
Surgeries & Interventions November 17, 2022
Cryoablation as a First-Line AFib Therapy November 17, 2022
Cryoablation outperforms antiarrhythmic drugs as a first-line defense against AFib.
Cardiology Pharmaceuticals November 14, 2022
SPORT: Statins Obliterate OTC Heart Supplements November 14, 2022
Six widely used dietary supplements promoted for improving heart health – including brands of fish oil, cinnamon, garlic and turmeric – were not as effective as rosuvastatin at lowering “bad” cholesterol more after 28 days of use.
Cardiology Pharmaceuticals November 10, 2022
Amgen’s Olpasiran Slashes Lp(a) Levels November 10, 2022
The Ocean(a)-DOSE trial made a splash at AHA this year, providing new insight into olpasiran’s potential to reduce Lp(a) levels in patients with ASCVD. In the phase 2 trial, 75 mg or more of the Amgen siRNA therapy delivered at least every three months basically obliterated Lp(a) levels.
Artificial Intelligence November 7, 2022
CW Q&A: Us2.ai’s Strain Analysis Feature November 7, 2022
In this Cardiac Wire Q&A, we sat down with Us2.ai president Yoran Hummel to discuss Us2.ai’s soon-to-be-released automated strain analysis feature.
Cardiology Business November 2, 2022
J&J to Buy Abiomed in $16.6B Deal November 2, 2022
Johnson & Johnson has struck a deal to buy Impella heart pump manufacturer Abiomed for $16.6B, expanding its cardiovascular care portfolio.
Cardiac Imaging 20221031
CW Q&A: Cleerly’s Image Transfer Solution 20221031
We sat down with Cleerly CTO Nick Nieslanik to learn about how Cleerly is tackling the image transfer problem with their new solution, Proxy.
Surgeries & Interventions 20221026
Persistent AFib Breakthrough 20221026
The debate around persistent AFib treatment has continued among electrophysiologists for decades. Contrary to an existing evidence base that shows additional ablation beyond PVI adds nothing, this RCT found that electrically isolating areas of low-voltage did improve AFib suppression.
Surgeries & Interventions 20221021
Abiomed’s Impella Achievements 20221021
Abiomed is celebrating a string of Impella achievements this month, including a new FDA clearance, favorable study results, and, perhaps most importantly, the final wrap-up of Impella’s post-approval studies.
Artificial Intelligence 20221019
HeartFlow Adds Plaque and RoadMap Analysis 20221019
HeartFlow announced the FDA clearance of its new Plaque and RoadMap Analysis AI solutions, making it the “first and only” company to non-invasively assess CAD using anatomy, physiology, and plaque data from coronary CTA exams.
Cardiology Pharmaceuticals 20221013
COVID Drug Paxlovid Interacts with Heart Medications 20221013
A review paper in JACC warns that the COVID antiviral Paxlovid may interact with common heart medications, potentially complicating treatment options.
Cardiology Pharmaceuticals 20221012
Merck’s $11B Acceleron Merger is Paying Off 20221012
Merck just announced that its pulmonary arterial hypertension drug candidate \delivered positive results in a pivotal Phase 3 clinical trial, potentially paving the way for a multibillion-dollar therapeutic and new hope for PAH patients.
Guidelines 20221009
Challenging the Salt Restriction Norm 20221009
A new study challenges the routine practice of restricting salt consumption in acute heart failure cases.
